• Mortality and cancer incidence in patients with balanced Robertsonian Translocations: a national cohort study 

  Schoemaker, M; Jones, ME; Swerdlow, A
• Mortality and cancer incidence in carriers of constitutional t(11;22)(q23;q11) translocations: a prospective study. 

  Schoemaker, MJ; Jones, ME; Swerdlow, AJ
• Mortality and cancer incidence in carriers of constitutional t(11;22)(q23;q11) translocations: a prospective study. 

  Schoemaker, MJ; Jones, ME; Higgins, CD; Wright, AF; UK Clinical Cytogenetics Group; Swerdlow, AJ (2018-11-29)

  The constitutional t(11;22)(q23;q11) translocation is the only recurrent non-Robertsonian translocation known in humans. Carriers are phenotypically normal and are usually referred for cytogenetic testing because of multiple ...
• The genomic landscape of plasma cells in systemic light chain amyloidosis. 

  Boyle, EM; Ashby, C; Wardell, CP; Rowczenio, D; Sachchithanantham, S; Wang, Y; Johnson, SK; Bauer, MA; Weinhold, N; Kaiser, MF; Johnson, DC; Jones, JR; Pawlyn, C; Proszek, P; Schinke, C; Facon, T; Dumontet, C; Davies, FE; Morgan, GJ; Walker, BA; Wechalekar, AD (2018-11-16)
• Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition? 

  Pawlyn, C; Loehr, A; Ashby, C; Tytarenko, R; Deshpande, S; Sun, J; Fedorchak, K; Mughal, T; Davies, FE; Walker, BA; Morgan, GJ (2018-07)

  PARP inhibitors can induce synthetic lethality in tumors characterized by homologous recombination deficiency (HRD), which can be detected by evaluating genome-wide loss of heterozygosity (LOH). Multiple myeloma (MM) is a ...

View more